Advertisement
Advertisement
U.S. Markets open in 6 hrs 59 mins
Advertisement
Advertisement
Advertisement
Advertisement

Enzo Biochem, Inc. (ENZ)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
2.3800-0.0200 (-0.83%)
At close: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.4000
Open2.3915
Bid2.0300 x 1100
Ask2.9000 x 800
Day's Range2.3100 - 2.4300
52 Week Range2.2300 - 4.1500
Volume44,558
Avg. Volume59,831
Market Cap115.363M
Beta (5Y Monthly)0.78
PE Ratio (TTM)23.80
EPS (TTM)0.1000
Earnings DateMar 14, 2022 - Mar 18, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Simply Wall St.

    Investors in Enzo Biochem (NYSE:ENZ) have unfortunately lost 73% over the last five years

    Some stocks are best avoided. We don't wish catastrophic capital loss on anyone. Spare a thought for those who held...

  • GlobeNewswire

    Enzo Biochem Announces New York State Department of Health Approval of HPV Molecular Diagnostic Test

    Approval adds HPV to menu of tests available on Enzo’s GenFlex® platform, which includes COVID-19 PCR and CT/NG/TVNEW YORK, NY, April 19, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, announced that it has received approval from the New York State Department of Health (DOH) for its AMPIPROBE® HPV test. The AMPIPROBE® HPV test is Enzo’s PCR-based test designed to detect 14 high-risk human papillomavirus (HPV) vari

  • GlobeNewswire

    Enzo Biochem Reports Results of its Annual Meeting of Shareholders

    FOR IMMEDIATE RELEASE All Four Proposals Approved NEW YORK, NY, April 12, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, announced the approval of all proposals presented at its most recent Annual Meeting of Shareholders. “Approval of these proposals improves our corporate governance and allows our refreshed leadership team to further prioritize shareholder-friendly initiatives,” stated Hamid Erfanian, Chief Execu

Advertisement
Advertisement